Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022
Cara Therapeutics (Nasdaq: CARA) will host a conference call on August 8, 2022, at 4:30 p.m. ET to discuss its Q2 2022 financial results and provide a corporate update. The call will be available via audio webcast, with a replay accessible on the company's website. Cara Therapeutics specializes in developing treatments for pruritus, notably with KORSUVA™ (difelikefalin) injection, the first FDA-approved treatment for moderate-to-severe pruritus in kidney disease patients undergoing hemodialysis. The company is also advancing oral formulations for other conditions.
- Cara's KORSUVA™ is the first FDA-approved treatment for pruritus in hemodialysis patients.
- The company is progressing with Phase 3 programs for oral difelikefalin targeting multiple pruritus conditions.
- None.
STAMFORD, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report second quarter 2022 financial results and provide a corporate update.
To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN.
A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
About Cara Therapeutics
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.
MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com
INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com
FAQ
When is Cara Therapeutics' Q2 2022 financial results announcement?
What product does Cara Therapeutics specialize in?
Where can I access the Cara Therapeutics conference call?
What is KORSUVA™ used for?
